Prothena (PRTA) Earns News Impact Score of 0.08
News articles about Prothena (NASDAQ:PRTA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Prothena earned a coverage optimism score of 0.08 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.6139104629834 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Prothena (NASDAQ:PRTA) opened at $41.01 on Monday. Prothena has a twelve month low of $37.99 and a twelve month high of $70.00.
Prothena (NASDAQ:PRTA) last posted its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.04. Prothena had a negative return on equity of 34.40% and a negative net margin of 562.19%. The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.28 million. During the same quarter last year, the firm earned ($1.26) earnings per share. The company’s revenue was down 33.6% on a year-over-year basis. sell-side analysts predict that Prothena will post -4.27 EPS for the current year.
Several equities research analysts have issued reports on PRTA shares. Deutsche Bank reaffirmed a “buy” rating on shares of Prothena in a report on Sunday, October 1st. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena in a report on Friday, September 29th. Evercore ISI started coverage on Prothena in a report on Wednesday, August 16th. They set an “outperform” rating and a $83.00 price target for the company. ValuEngine downgraded Prothena from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Finally, SunTrust Banks reaffirmed a “buy” rating and set a $75.00 price target on shares of Prothena in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $76.75.
In related news, insider Tara Nickerson sold 17,500 shares of the business’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $63.60, for a total value of $1,113,000.00. Following the completion of the transaction, the insider now owns 19,500 shares of the company’s stock, valued at $1,240,200. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $64.17, for a total value of $224,595.00. The disclosure for this sale can be found here. Insiders have sold 29,424 shares of company stock valued at $1,922,787 in the last three months. Insiders own 3.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Prothena (PRTA) Earns News Impact Score of 0.08” was first published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/prothena-prta-earns-news-impact-score-of-0-08/1756783.html.
Prothena Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.